tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating

Immix Biopharma’s Strategic Expansion and Promising Trial Results Reinforce Buy Rating

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, retaining the price target of $7.00.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Robert Burns has given his Buy rating due to a combination of factors related to Immix Biopharma’s recent progress and potential in the clinical trial landscape. The expansion of the NEXICART-2 trial to include 18 sites across the U.S. is a significant development, as it is expected to accelerate patient enrollment and advance the company’s timeline towards a Biologics License Application submission for FDA approval. This strategic move is seen as a positive step in enhancing the company’s prospects in the competitive field of biotechnology.
Moreover, the interim data from the NEXICART-2 trial presented at the ASCO meeting showed promising results, with a 100% response rate and a 70% complete response rate among patients treated with NXC-201. The absence of severe adverse events further underscores the potential of NXC-201 as a treatment for relapsed/refractory AL amyloidosis, a condition with limited current treatment options. These encouraging clinical outcomes, coupled with the projected peak sales of approximately $475 million by 2035, reinforce the Buy rating and the 12-month price target of $7.

According to TipRanks, Burns is an analyst with an average return of -15.3% and a 32.14% success rate. Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Exelixis, and Zymeworks.

Disclaimer & DisclosureReport an Issue

1